| Literature DB >> 29357380 |
Xavier Debussche1,2, Stéphane Besançon3, Maryvette Balcou-Debussche4,5, Cyril Ferdynus2,6, Hélène Delisle7, Laetitia Huiart2,6,8, Assa T Sidibe9.
Abstract
OBJECTIVES: Our objective was to evaluate the effectiveness of peer-led self-management education in improving glycaemic control in patients with type 2 diabetes in a low-income country (Mali).Entities:
Mesh:
Substances:
Year: 2018 PMID: 29357380 PMCID: PMC5777645 DOI: 10.1371/journal.pone.0191262
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flow chart of participants.
ST2EP trial.
Clinical and biological characteristics at baseline of participants allocated to peer-led structured patient education (intervention) or to conventional care alone (control).
| Total (n = 151) | Intervention (n = 76) | Control (n = 75) | |
|---|---|---|---|
| Gender (female, n, %) | 115 (76.2) | 57 (75.0) | 58 (77.3) |
| Age, years | 52.5 (9.8) | 53.9 (9.8) | 51.1 (9.6) |
| BW, kg | 78.2 (15.6) | 77.7 (16.4) | 78.7 (14.7) |
| BMI, kg/m2 | 28.6 (5.4) | 28.3 (5.4) | 28.8 (5.5) |
| Waist circumference, cm | 93.9 (11.9) | 93.7 (12.1) | 94.1 (11.6) |
| BMI 25.0–29.9 | 48 (31.8%) | 21 (27.6%) | 27 (36.0%) |
| BMI≥30.0 | 62 (41.1%) | 34 (44.7%) | 28 (37.3%) |
| BP Diastolic, mm Hg | 81.6 (10.6) | 82.9 (10.5) | 80.3 (10.6) |
| BP Systolic, mm Hg | 129.9 (23.9) | 132.8 (26.9) | 127.1 (20.1) |
| HbA1c, % | 10.7 (1.8) | 10.6 (1.8) | 10.8 (1.9) |
| No treatment / Diet only | 13 (8.6%) | 7 (9.2%) | 6 (8.0%) |
| Oral anti-diabetic only | 92 (60.9%) | 45 (59.2%) | 47 (62.7%) |
| Insulin only | 32 (21.2%) | 15 (19.4%) | 17 (22.7%) |
| Insulin and oral anti-diabetic | 14 (9.3%) | 9 (11.8%) | 5 (6.7%) |
| Knowledge score | 5.2 (1.2) | 5.2 (1.2) | 5.2 (1.3) |
Values are n (%) or mean (SD). BMI = Body Mass Index. BW = Body weight. BP = Blood pressure
Changes in biomedical outcomes from baseline to 12 months.
The ST2EP trial in Mali. Data are mean (CI 95%).
| Intervention group | Control group | p-value | |
|---|---|---|---|
| Body Mass Index, kg/m2 | -1.65 (-2.25; -1.06) | 0.05 (-0.71; 0.81) | 0.0005 |
| Waist circumference, cm | -3.34 (-5.56;-1.13) | 2.65 (0.20;5.09) | 0.0003 |
| Systolic BP, mm Hg | -6.46 (-11.63;-1.28) | 3.57 (-0.17;7.31) | 0.003 |
| Diastolic BP, mm Hg | 0.40 (-2.27;3.07) | 2.00 (-0.77;4.77) | 0.36 |
| HbA1c, % | -1.05 (-1.54; -0.56) | -0.15 (-0.56; 0.26) | 0.006 |
| Knowledge score | 1.06 (0.70;1.42) | 0.61 (0.23;0.99) | 0.17 |
Anti-diabetic and anti-hypertensive treatment in intervention group and in control group at baseline and at 12-month follow-up (FU).
| Total | Intervention group | Control | p-value | |
|---|---|---|---|---|
| Insulin | 43 (28.5%) | 22 (28.9%) | 21 (28.0%) | 0.90 |
| OAD only | 108 (71.5%) | 55 (72.4%) | 53 (70.7%) | 0.82 |
| Combination of 2 OADs | 108 (71.5%) | 55 (72.4%) | 53 (70.7%) | 0.82 |
| Calcium channel blockers | 7 (4.6%) | 5 (6.6%) | 2 (2.7%) | 0.44 |
| Beta Blockers | 4 (2.6%) | 2 (2.6%) | 2 (2.7%) | 0.99 |
| Angiotensin Receptor Blockers | 23 (15.2%) | 15 (19.7%) | 8 (10.7%) | 0.12 |
| Central | 1 (0.7%) | 1 (1.3%) | 0 (0.0%) | 1.00 |
| Diuretics | 1 (0.7%) | 1 (1.3%) | 0 (0.0%) | 1.00 |
| Insulin | 36 (25.7%) | 17 (24.3%) | 19 (27.1%) | 0.70 |
| OAD | 102 (72.9%) | 51 (72.9%) | 51 (72.9%) | 1.00 |
| Combination | 100 (71.4%) | 50 (71.4%) | 50 (71.4%) | 1.00 |
| Calcium channel blockers | 11 (7.9%) | 6 (8.6%) | 5 (7.1%) | 0.75 |
| Beta Blockers | 6 (4.3%) | 3 (4.3%) | 3 (4.3%) | 1.00 |
| Angiotensin Receptor Blockers | 36 (25.7%) | 22 (31.4%) | 14 (20.0%) | 0.12 |
| Central | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | NC |
| Diuretics | 3 (2.1%) | 1 (1.4%) | 2 (2.9%) | 1.00 |
Data are n (%)
*OAD: Oral Antidiabetic therapy comprising metformin and/or sulfonylurea and/or alpha-glucosidase inhibitors.
**Combination of 2 OAD: Combination of metformin and sulfonylurea
Fig 2Evolution of HbA1c levels between baseline and 12 months–levels in % and 95% confidence interval.
Fig 3Evolution of body mass index, waist circumference and blood pressure between baseline and 12 months– 95% confidence interval.
Knowledge score changes between baseline (T0) and end of follow-up (12 months) in intervention group (n = 70) and in control group (n = 70).
| Knowledge score domains (EFU–T0) | Total | Intervention group | Control | p-value |
|---|---|---|---|---|
| Symptoms | 0.04 (0.40) | 0.13 (0.39) | -0.06 (0.39) | 0.003 |
| Treatments | 0.00 (0.47) | 0.03 (0.46) | -0.04 (0.47) | 0.39 |
| Treatments adherence | 0.10 (0.24) | 0.12 (0.22) | 0.07 (0.26) | 0.17 |
| Sign of gravity | 0.00 (0.24) | 0.00 (0.24) | 0.01 (0.25) | 0.73 |
| Symptoms of hypoglycemia | 0.12 (0.31) | 0.12 (0.31) | 0.12 (0.31) | 0.94 |
| Hypoglycemia management | 0.04 (0.43) | 0.09 (0.43) | 0.00 (0.44) | 0.26 |
| Diabetic foot | 0.02 (0.22) | 0.02 (0.23) | 0.02 (0.22) | 0.92 |
| Physical activity | 0.39 (0.54) | 0.40 (0.53) | 0.37 (0.55) | 0.78 |
| Diet | 0.11 (0.21) | 0.13 (0.22) | 0.10 (0.20) | 0.40 |
Changes are scores at end of follow-up minus scores at baseline. Data are mean (SD).
* p<0.05 for increase between baseline and end of FU.